Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand
Authors: Thu, Aung Myint
Kittiyod Poovorawan
Chatporn Kittitrakul
Apichart Nontprasert
Natthida Sriboonvorakul
Weerapong Phumratanaprapin
Pisit Tangkijvanich
Wattana Leowattana
Polrat Wilairatana
Mahidol University. Faculty of Tropical Medicine. Department of Clinical Tropical Medicine
Keywords: Open Access article;Nephrotoxicity;Antiviral agents;Nucleotide;Chronic hepatitis B;Thailand
Issue Date: 2015
Citation: BMC Pharmacology and Toxicology. Vol.16, (2015), 38
Abstract: Background: There is increasing concern about the potential for nephrotoxicity in patients with chronic hepatitis B (CHB) treated long-term with nucleotide analogs. Methods: We examined renal dysfunction and its associated risk factors in patients with CHB treated with antiviral regimens containing either nucleosides or nucleotide analogs. We undertook a retrospective cohort study from 2006 to 2014 at the Hospital for Tropical Diseases, Bangkok, Thailand, and analyzed the data of 102 patients with a median follow-up time of 44.5 months (range 4–101 months). Results: Seventy-three patients were treated with an antiviral regime containing a nucleoside analog, and 29 with a regime containing a nucleotide analog. Abnormally elevated serum creatinine concentration was observed in 12 patients (11.8 %) after 8 years of treatment. Thirty one percent of patients treated with nucleotide analogs had elevated serum creatinine levels and three of these patients (10.3 %) developed nephrotoxicity. In contrast, serum creatinine concentrations were elevated in three of the 73 patients treated with a nucleoside analog (4.1 %), and none developed nephrotoxicity. The incidence of renal dysfunction by the nucleotide analog regimen was cumulative, with 11.1, 21.0, 26.5 and 47.6 % of patients affected after 2, 4, 6 and 8 years, respectively. Univariate and multivariate analysis indicated that a nucleotide analog-based regimen significantly predicted renal dysfunction (odds ratio 10.5, 95 % confidence intervals 2.6–42.4, P <0.001). Conclusion: The long-term use of nucleotide analogs increased the risk of nephrotoxicity in patients with CHB. Thus, the regular assessment of renal function is recommended for all patients with CHB, particularly those treated with a nucleotide analog.
Appears in Collections:TM-Article

Files in This Item:
File Description SizeFormat 
tm-ar- kittiyod-2015.pdf1.35 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.